Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OREX 4.73 -0.16 (-3.27%)
price chart
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Patients now have a third drug to treat their obesity. Today, Orexigen (NASDAQ: OREX ) and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave .
Orexigen Wins US FDA Approval for Weight-Loss Pill  Businessweek
FDA approves weight-loss drug Contrave  Kansas City Star
Related articles »  
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Obesity Pill Approval Fails to ...
Tomahawk, WI 09/15/2014 (Basicsmedia) - Patients suffering from obesity can finally heave a sigh of relief after the Food and Drug's administration approved Orexigen Therapeutics, Inc. (NASDAQ:OREX)'s obesity drug, Contrave. Contrary to expectations ...
Orexigen Therapeutics Stumbles Off the Edge of a Cliff (ARNA, VVUS, OREX)  SmallCap Network
Orexigen Therapeutics Sees Large Increase in Short Interest (OREX)  Intercooler
Related articles »  
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Editor's Note: The article below was updated to clarify that Saxenda is a 3 mg dose of liraglutide, as compared to Victoza (1.2/1.8 mg dose).
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And ...  Bidness ETC
Orexigen's Contrave Approved by FDA  NBC 7 San Diego
Related articles »  
Orexigen Therapeutics, Inc. (NASDAQ: OREX) Upcoming FDA Decision in Early ...
Orexigen Therapeutics, Inc. (NASDAQ: OREX) awaits the approval of their lead candidate, the anti-obesity drug Contrave, also known as NB32.
Traders Favorite: Orexigen Therapeutics, Inc. (NASDAQ:OREX), IGI ...  Market News Call
Related articles »  
Orexigen Therapeutics (OREX) Marked As A Dead Cat Bounce Stock
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
Wells Fargo & Co. Increases Orexigen Therapeutics Price Target to $15.00 ...  WKRB News
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Stock Sinks Despite FDA ...  BasicsMedia
Related articles »  
FDA Expected To Approve Two More Weight Loss Drugs
The US Food and Drug Administration (FDA) which approved two weight-loss drugs after a gap of 13 years, is expected to announce its decision regarding Orexigen Therapeutics, Inc.'s (OREX) obesity drug on September 11. On the same day, the regulator ...
Related articles »  
On top of hot stocks: Zynga Inc (NASDAQ:ZNGA), Orexigen Therapeutics, Inc ...
Zynga Inc (NASDAQ:ZNGA) extended gains on Wednesday following news that the social and mobile game company has revealed new details concerning its upcoming mobile runner, called Looney Tunes Dash.
Related articles »  
Falling Stocks: VirnetX Holding Corporation(NYSEMKT:VHC), Orexigen ...
Orexigen Therapeutics, Inc.(NASDAQ:OREX) suffered a 1.41% decrease in value yesterday as the stock fell seven cents to move to a closing price of $4.89.
Orexigen Therapeutics Inc. (OREX) Drops 10.51% on September 11
Orexigen Therapeutics Inc. (OREX) was one of the Russell 2000's biggest losers for September 11 as the stock slid 10.51% to $5.28, a loss of $0.62 per share.
Related articles »  
Orexigen Therapeutics Sees Unusually-High Trading Volume After Insider ...
Orexigen Therapeutics logo Shares of Orexigen Therapeutics (NASDAQ:OREX) saw unusually-strong trading volume on Monday after an insider bought additional shares in the company, StockRatingsNetwork.com reports. Approximately 8,594,312 shares ...